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ABSTRACT 
Purpose 
Recently, carotid-sparing intensity-modulated radiotherapy (CS-IMRT) for early laryngeal 
glottis (T1/T2N0M0) cancer has generated interest in the hope of avoiding long-term carotid 
toxicity, as well as concerns relating to geographical misses and long-term normal tissue 
toxicity.  The aim of this review was to summarise the current literature on CS-IMRT for early 
glottis cancer, with particular focus on definitions of target volumes and the carotid arteries 
as organs at risk. In addition, we make suggestions for standardization of these structures, 
dose constraints, and dose reporting.   
 
Materials and methods 
From 73 references, 16 articles met the criteria for inclusion in this systematic review.  
These papers described 2 case reports, 11 planning studies, and 3 prospective studies. 
 
Results 
There was variation in all target volume definitions with no clear consensus.  The greatest 
variability was in clinical target volume definition.   Carotid artery and spinal cord delineation 
were not always defined and most studies did not utilize a carotid artery constraint.  Of the 8 
studies that reported carotid artery delineation, no two studies delineated the same length of 
carotid artery, yet most studies reported mean doses.  Most studies utilized intensity-
modulated radiotherapy with 3 – 7 fields.  Five studies used arc therapy and 2 studies used 
tomotherapy. 
 
Conclusion 
This review highlights a lack of consensus in target volume definitions in CS-IMRT.  
Ultimately, long-term prospective data are required to show the benefit of CS-IMRT.  Pooled 
data will prove useful as most studies will report on small numbers of patients.  Therefore, 
adopting a consensus now on target volume definition, dose constraints and dose reporting 
will be crucial. 
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INTRODUCTION 
 
The treatment of early laryngeal glottis (T1/T2N0M0) cancer involves the use of primary 
radiotherapy (RT), typically using two parallel-opposed lateral radiotherapy beams.  
Consequently, the carotid arteries are usually included in the treatment field as collateral 
structures, exposing them to endothelial injury and subsequent risk of stroke or transient 
ischaemic attack (1).  Treating the entire larynx allows for an adequate margin (planning 
target volume (PTV)) to account for movement during swallowing, which can be up to 3.5 cm 
in the superior-inferior direction (2).   Vocal cord motion during regular breathing (3) should 
also be accounted for when treatment volumes are significantly reduced. 
 
Recently, carotid-sparing intensity-modulated radiotherapy (IMRT) has generated interest in 
the hope of avoiding long-term carotid toxicity, as well as concerns relating to geographical 
misses and long-term normal tissue toxicity (4).  This technique requires the larynx clinical 
target volume (CTV) and PTV margins to be redefined to address the balance between local 
control and late normal tissue toxicity. Adequate allowance for laryngeal movement during 
swallowing and breathing is crucial in determining a PTV that balances vocal cord 
displacement and sparing the carotid arteries. 
 
The aim of this review was to summarise the current literature on carotid-sparing RT for 
early glottis cancer, with particular focus on definitions of target volumes and the carotid 
arteries as organs at risk (OARs), and suggestions for standardization of these structures, 
dose constraints, and dose reporting.   
 
Materials and methods 
Search strategy and selection criteria 
We performed a systematic search of Pubmed (1st January 2000 to 31st December 2015) for 
English language articles using the search terms: “carotid”, “radiotherapy”, “larynx”.  The 
abstracts or available data of this search were reviewed to include or exclude references for 
full text review.  Articles reporting on patients treated with IMRT for early glottis cancer or 
planning studies investigating carotid-sparing IMRT in this population were eligible for 
inclusion, as were case reports.  Studies that did not investigate or report radiation doses to 
the carotid arteries were excluded from this review. 
 
Relevant references not clearly identifying patient populations or study design were included 
in the initial review to avoid erroneous exclusion.  The full text articles from the selected 
references were scrutinized to select the final set of articles for review and analysis.  The 
reference lists of these articles were also reviewed, and references from relevant titles were 
obtained and reviewed according to the above selection criteria. 
 
Data abstraction and analysis 
The outcomes of interest were: target volume (gross tumour volume (GTV), CTV, PTV) 
definitions, carotid and spinal cord OAR definition, carotid and spinal cord OAR dose 
constraint and reporting.  Field set-up, planning technique and dose prescription were also 
recorded.  Each parameter was considered and reported separately. 
 
Results 
The search revealed 73 references (Fig 1).  Of these, 43 were published after 1st January 
2000, and confirmed the concept of carotid-sparing RT is a recent one.  Fifteen references 
met the inclusion criteria from the initial search. Two studies were based on the same patient 
cohort and reported twice – the reference not related to carotid-sparing RT was excluded in 
each case (15 – 2 = 13).  Full text review of these articles revealed a further three references 
that met the inclusion criteria.  Therefore, a total of 16 references met the inclusion criteria 
for this review (5-20).  These included 2 case reports, 11 planning studies, and 3 prospective 
studies (one published in abstract from only). 
 
Outlining (Table 1) 
 
Gross tumour volume (GTV) 
The gross tumour volume (GTV) definition varied from none (N = 5) (7, 9, 11, 17, 19) to 
bilateral true vocal cords (5, 8). This was defined based on endoscopy findings and any 
diagnostic imaging for some studies (6, 20).  Gomez et al (5) defined the GTV on CT 
findings only.  Some studies did not delineate a GTV (7, 9, 11, 17, 19).  Mourad et al (13) did 
not report any target volume delineation for any structures. 
 
Clinical target volume (CTV) 
There was considerable variation in clinical target volume (CTV) delineation. Most studies 
included the cartilaginous framework of the larynx (vocal cords, arytenoids, 1.5 cm of 
subglottis), whilst others restricted the CTV to a 0.3 - 0.5 cm margin on the true vocal cords 
(8, 20) or the whole involved vocal cord (11).  In general, the major modification to the CTV 
was to bring the posterior border forward to cover the arytenoids and cricoid cartilage and 
exclude the hypopharynx.  
 
Planning target volume (PTV) 
Planning target volume (PTV) was constructed by expanding the CTV in the following range 
of ways: from no expansion (6, 10) to a uniform 1 cm expansion (5, 18).  Some studies (12, 
15) applied standard field borders instead of a defined PTV.  Prescribed doses varied – the 
most common prescribed dose (N = 9) was 63 Gy/28 fractions. 
 
Organs at risk (OARs) 
Spinal cord 
Most studies did not define spinal cord delineation or spinal cord planning at risk volume 
(PRV).  Two studies (7, 9) defined the spinal cord 1 cm superior and inferior to the PTV and 
a 3 mm.PRV Riegel et al (12) delineated the spinal cord to cover the superior and inferior 
extent of the CTV.  Most studies did not report the spinal cord constraints.  Those that did 
report constraints varied from a maximum dose of < 20 Gy (6) to a maximum dose of < 45 
Gy (7, 9, 10, 17).  
 
Carotid arteries 
Some studies contoured both carotid arteries as a single organ at risk (see Table 1).  Others 
defined a left and right carotid OAR.   The superior and inferior extent of the carotid arteries 
varied, and often not reported.  Only 3 studies (7, 9, 19) applied a 3-5 mm PRV.  Carotid 
artery constraints were applied in only 2 studies: Riegel et al (12) (mean dose as low as 
possible), and Zumsteg et al (mean dose <52 Gy) (18).  
 
Planning techniques (Table 2) 
Most studies utilized IMRT with a 3 to 9-field technique.  Four studies (10, 12, 19, 20) used 
arc therapy. Two studies developed tomotherapy plans to deliver RT (14, 17).  The study by 
Matthiesen et al also developed RT plans using proton therapy and utilized 3 uniform 
scanning beams (19).  
 
Image-guided radiotherapy (IGRT) 
Five studies used daily image guidance (6, 8, 14, 16, 20).  The CTVs and PTVs in these 
studies were smaller than conventional fields and did not include all the cartilaginous 
structures of the larynx.  Chatterjee et al was the only study to maintain the traditional larynx 
CTV, but did edit the PTV away from the carotid arteries (14). 
 
Kinematics 
Two studies (17, 20) advised patients not to swallow during treatment in order to try and 
minimize the displacement that occurs during swallowing.  Neither study described whether 
patient compliance during treatment was assessed.  Single vocal cord irradiation was 
investigated in 2 studies (13, 16), but only one study utilized daily image guidance with cone 
beam CT (CBCT) (16).   
DISCUSSION 
This review highlights a lack of consensus in target volume definitions.  As field sizes get 
smaller with carotid-sparing techniques, it is even more important to ensure the tumour is 
always encompassed within the treated volume.  GTV delineation is, therefore, crucial and 
endoscopy and diagnostic imaging findings should be incorporated in this process and 
reported in studies.  Four-dimensional CT scanning (3) and magnetic resonance imaging co-
registration (21) may improve GTV localization and, perhaps more importantly, quantify 
vocal cord motion during breathing and allow for adaptation of treatment to account for this. 
It is also clear that CTV definition is variable and should be clarified before this technique 
becomes standard clinical practice and studies begin to report outcome data.  Risk of 
microscopic spread to the cartilaginous structures of the larynx is low in correctly staged 
early glottis cancers (hence, some of these patients may be adequately treated with laser 
resection), yet these are often included in the CTV.  CTV definitions also appear to have 
been defined according to laryngeal motion and, strictly speaking, should be reclassified as 
PTV definitions as they refer to the internal target volume.  We believe PTV delineation 
should be dependent on whether or not centres have access to daily IGRT.  We advocate 
more generous PTV margins that include both vocal cords and other cartilaginous structures 
of the larynx for those centres without an IGRT programme.   
 
The larynx PTVs in most studies were similar to a standard larynx field except in the 
posterior direction, where the field is reduced to allow for carotid-sparing.  This PTV did not 
differ dramatically from standard practice and would be relatively easy to introduce into 
clinical practice.  Image-guided radiotherapy and 4-dimensional CT-planning to account for 
motion during breathing, as well as swallowing, would potentially allow for further reduction 
in PTV margins (22).   
It is important to remember that the time spent swallowing during a patient’s treatment has 
been calculated to be less than 1% (23, 24).  One study reported maximum anterior and 
superior displacements of 6.3 mm and 11.5 mm, respectively (23), and the other reported 
maximum displacements of 25 mm (superior) and 8.3 mm (anterior) (24).  The obvious 
question is the need to account for swallowing if this accounts for only 1% of a patient’s time 
on treatment.  We would argue that, in the absence of an advanced IGRT programme with 
daily imaging, a dramatic shrinkage in treatment volumes is not advisable.  It is also 
important to account for the vocal cord displacement that occurs during breathing.  In the 
context of a multi-centre clinical trial, the use of PTV margins and treatment volumes that are 
easy to implement for most centres and which do not differ dramatically from current 
standard of care seems a sensible approach.  
 
It would perhaps be better to label carotid OARs as ipsilateral and contralateral carotid 
arteries, rather than left and right carotid OARs, to reflect their proximity to the GTV, as 
some investigators chose to spare the contralateral vocal cord or arytenoid.  In addition, a 
single carotid OAR that incorporates both carotid arteries will underestimate the mean 
carotid dose in this setting.  It is important to standardize delineation of the carotid OAR and 
PRV in order to determine mean doses as accurately as possible and realistically account 
for expansion and contraction during the cardiac cycle.   Previous studies (5, 6, 16) have 
reported mean carotid doses of between 18 to 29 Gy, but none of these studies defined the 
carotid OAR or applied PRV margins.  Chera et al (7) contoured carotid OARs 1 cm superior 
and inferior to the PTV and applied 3 mm PRV margins.  Most studies reported carotid artery 
mean doses yet there is no consensus as to the length of carotid artery included in the OAR.  
Variability will result in significant differences in mean carotid artery doses and may not be 
comparable from study to study. 
 
We recommend defining the carotid OAR as the extra-cranial extent of the carotid artery 
(inferiorly from the aortic arch on the left and brachiocephalic trunk on the right and extended 
superiorly to at least 2.5 cm superior to the hyoid bone).  We believe this carotid OAR is 
reasonable to calculate realistic mean doses to a defined, reproducible length of carotid 
artery.  The average diameter of the common carotid artery is around 6.1 (SD 0.8) mm for 
females and 6.5 (SD 1.0) mm in males (25).  During the cardiac cycle, the carotid artery 
luminal diameter can change by up to 15% (26).  A 15% increase in 6.5 mm is 0.98 mm, so 
a further 1 mm margin (before applying the PRV) adequately accounts for carotid diameter 
changes during the cardiac cycle.   
 
The lack of a carotid OAR dose constraint for most of these studies is a weakness and 
should be more clearly defined in future prospective studies.  The length/volume/diameter of 
carotid artery does not appear to be important.  Rather, the carotid artery behaves as a 
serial organ and it is the dose of RT to a particular section of artery that is important (1).   It 
would be reasonable to set a stringent constraint of a maximum dose of <35 Gy (27, 28) to 
demonstrate a positive impact of carotid-sparing RT on future neurological events. 
 
The spinal cord should be contoured (from the foramen magnum superiorly to at least 2.5 
cm below the PTV) and a spinal cord PRV created by a 3 - 5 mm expansion (depending on 
institutional policy) in all directions of the spinal cord OAR.  It is important to note that 
reported spinal cord constraints are derived based on standard fractionation (2 Gy per 
fraction) and some studies used hypofractionated regimens (14, 15). This becomes 
important when spinal cord dose constraints are set at 45 Gy for IMRT or arc therapy.  
Spinal cord constraints should be stringent and reported when treating patients with IMRT. 
 
Newer radiation techniques such as proton therapy may provide incremental benefits for 
carotid-sparing (19).  The use of MRI for RT planning may further enhance tumour 
localization and quantification of motion during treatment (29).  These techniques, however, 
are only useful and comparable with other techniques and studies if accepted definitions of 
target volume delineation are applied. 
There are some limitations to consider.  Tumour location may dictate feasibility of carotid-
sparing, and this technique may only be reasonable for tumours located on the anterior cord.  
With 4 dimensional CT planning and IGRT, vocal cord displacement can be more accurately 
studied in a prospective setting and potentially allow for further reduction in PTV margins.  
The use of magnetic resonance imaging in radiotherapy planning may allow for assessment 
of displacement of vocal cord tumour.  These techniques, however, will be restricted to 
centres with the relevant experience and may not be generally applicable.  Therefore, in 
order to address both carotid-sparing and local control, we would suggest that the technique 
that makes the greatest allowance for uncertainties in target volume delineation and RT 
planning would be applicable in most cancer centres that treat these tumours.  In the context 
of a clinical trial, multi-centre participation will be crucial for accrual and generalizability of 
results.    
CONCLUSION 
Ultimately, long-term prospective data are required to show the benefit of carotid-sparing.  
Lower RT dose to carotid arteries may reduce the incidence of radiation-induced 
atherosclerosis and subsequent stroke risk.  Pooled data will prove useful as most studies 
will report on small numbers of patients.  Therefore, adopting a consensus now on how to 
define target volumes, dose constraints and dose reporting will be crucial to allow this to 
occur in future. 
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Figure legends 
Figure 1  Flow diagram of literature search 
 
 
 
 Table 1.  Target volume definitions – gross tumour volume (GTV), clinical target volume (CTV), planning target volume (PTV), organs at risk 
(OAR), planning at-risk volume (PRV) 
 
Study GTV  CTV  PTV  OAR  
Gomez et al 2010 
[5]  
  
(N =    (N = 3) 
Bilateral 
TVC 
(defined on 
CT)  
larynx (false and true VC, ant + post 
commissure, arytenoids and aryepiglottic 
folds) and subglottic region, extending from 
the level of  hyoid bone to the bottom of  
cricoid  
0.5 and 1 cm Bilateral carotid OAR, not defined, no PRV 
 
Spinal cord not defined 
Rosenthal et al 
2010 [6] 
 
(N = 6) 
Gross 
tumour 
(defined on 
endoscopy 
and CT) 
Anterior limit = inside the skin as far as 
possible but to encompass thyroid cartilage 
with 5-mm margin  posterior = the posterior 
limit of  thyroid and cricoid cartilages. 
Minimum 4 cm x 4 cm field size used 
None Separate R and L carotid arteries, not defined. 
no PRV 
 
Spinal cord not defined 
 
Chera et al 2010 
[7] 
 
(N = 5) 
None CTV = arytenoids cartilages, false VCs, 
anterior and posterior commisures, TVCs, 
and 1 - 1.5 cm of subglottis.  
Two CTVs created: bilateral CTV + unilateral 
CTV 
3mm in lat and 
ant directions 
Bilateral carotid OAR 
Carotid PRV = 3 mm margin 
 
 
Spinal cord and carotid arteries contoured 1cm 
beyond superior and inferior extent of PTV 
 
Tiong et al 2011 
[8] (Abstract) 
 
(N = 50) 
Bilateral 
TVCs 
(Not 
defined) 
0.5 and 1cm margins on GTV (2 x CTVs) = 
CTV60 
Further 0.5 to 2 cm margin = CTV50 
0.5 cm None 
Sert F et al 2012 
[9] 
 
(N = 5) 
None CTV = arytenoids cartilages, false VCs, 
anterior and posterior commisures, TVCs, 
and 1 - 1.5 cm of subglottis.  
0.3 cm Bilateral carotid OAR 
Carotid PRV = 3 mm margin 
 
Spinal cord and carotid arteries contoured 1cm 
beyond superior and inferior extent of PTV 
 
Atalar et al 2012 
[10] 
 
(N = 5) 
Not defined CTV - encompass thyroid with 5 mm margin 
ant, cricoid, arytenoid, false VCs, ant and 
post commissures, TVCs and 1-1.5 cm of 
subglottis; the borders extended to  hyoid 
superiorly and to bottom of cricoid inferiorly 
None Left and right carotid OARs, length not defined, 
no PRV 
 
Spinal cord not defined 
Osman et al 2012 
[11] 
 
(N = 10) 
None Whole involved VC based on CT imaging – 
CTV66 
0.2 cm Bilateral carotid OAR 
Level of C2 to C6, no PRV 
 
Spinal cord not defined 
Riegel et al 2013 
[12] 
 
(N = 11) 
Not defined Whole larynx 
Sup – hyoid 
Inf bottom of cricoid 
Ant – skin 
Post – posterior to arytenoids 
0 Left and right carotid OARs contoured 1.2 cm 
superior and inferior of CTV, no PRV 
 
Spinal cord to cover superior and inferior 
extent of CTV 
Mourad et al 2013 
[13] (case report) 
 
(N = 1) 
Gross 
tumour 
(Not 
defined) 
Not defined Not recorded R carotid OAR, not defined, no PRV 
Chatterjee S et al 
2013 [14] 
 
(N = 5) 
Not defined Sup = cranial border of thyroid cartilage 
Inf = caudal edge cricoid 
Ant = ant edge thyroid cartilage 
Post = include arytenoid 
Lat = include entire thyroid cartilage 
0.5 cm, edited off 
carotid 
Left and right carotid OARs, no PRV 
Superior = Skull base  
Inferior= sternoclavicular joint 
 
Spinal cord not defined 
Garcez et al 2014 
[15] 
 
(N = 10) 
Not defined Not defined Not defined – 
standard 5.5 x 5.5 
cm fields centred 
on VCs 
8 cm length of left and right carotid, no PRV 
 
Spinal cord not defined 
Janssen et al 
2014 [16] 
 
(N = 77) 
Gross 
tumour 
(Not 
defined) 
10 – 15 mm 0.2 – 0.3 cm Left and right carotid OARs, not defined, no 
PRV 
 
Spinal cord not defined 
Hong et al 2015 
[17] 
 
(N = 10) 
None CTV = arytenoids cartilages, false VCs, 
anterior and posterior commisures, TVCs, 
and 1 - 1.5 cm of subglottis 
0.3 cm lat and 
ant, 0.1 cm post 
Bilateral carotid OAR, 2 cm superior and 
inferior to PTV, no PRV 
 
Spinal cord not defined 
Zumsteg et al 
2015 [18] 
 
(N = 48) 
Gross 
tumour 
(defined on 
endoscopy) 
Entire larynx, including ant and post 
commissures, and arytenoids, from top of  
thyroid cartilage to bottom of  cricoid 
1.0 cm Left and right carotid OARs, on slices of PTV, 
no PRV 
 
Spinal cord not defined 
Matthiesen et al 
2015 [19] 
 
(N =10) 
None CTV = arytenoids cartilages, false VCs, 
anterior and posterior commisures, TVCs, 
and 1 - 1.5 cm of subglottis. 
0.5 cm Bilateral carotid OAR, 1 cm superior and 
inferior to PTV, 3- 5 mm PRV 
 
Spinal cord not defined 
Ward et al 
2015 [20] 
(case report) 
 
(N = 1) 
Gross 
tumour 
(defined on 
endoscopy 
and CT 
CTV63 = GTV 
CTV51.8 = CTV63 + 3mm in sup-inf direction 
and extended to include both TVCs and 
ipsilateral arytenoid 
0.2 cm Left and right carotid OARs, not defined, no 
PRV 
 
Spinal cord not defined 
 
 
 
 
 
 
 
 
 
Table 2.  Planning constraints, dose reporting and dose prescription 
 
Study Spinal cord 
constraint 
Carotid 
constraint 
Carotid dose  
reported 
Field set-up Dose prescription Image guidance? 
Gomez et al 
2010 [5] 
None None Mean 3-4 anterior fields 63 Gy/28 (2.25 
Gy/fx) over 38 
days 
No – planning study 
Rosenthal et al 
2010 [6] 
V90 < 10 Gy 
Max dose 20 Gy 
 
None 
 
Mean 
Median 
V35, V50 
3 fields (0, 70, 290) 63 Gy/28 Yes – daily (planning study) 
Chera et al 2010 
[7] 
Max < 45 Gy None Median 
Max median point 
dose 
7 equispaced beams 63 Gy/28 (2.25 
Gy/fx) 
No – planning study 
Tiong et al 2011 
[8] 
Not reported None Not reported 5 fields 60 Gy/25  
50 Gy/25 
Yes - CBCT 
Sert F et al 2012 
[9] 
Max < 45 Gy None Median 
Mean 
V63, V50, V35 
9 fields 62.25 Gy/28 No – planning study 
Atalar et al 2012 
[10] 
Max < 45 Gy None Mean 
V35, V50 
3 or 5 – fields 
IMAT 
63 Gy/28 No – planning study 
Osman et al 
2012 [11] 
Not reported None Maximum 
V35 
5 fields 66 Gy/33 No – planning study 
Riegel et al 2013 
[12] 
Max < 25 Gy Mean carotid 
dose as low 
as possible 
Maximum 
Mean 
V63, V50, V35 
VMAT 
3-field IMRT 
63 Gy/28 No – planning study 
Mourad et al 
2013 [13] 
Not reported None Mean IMRT – fields not 
defined 
63 Gy/28 No 
Chatterjee S et 
al 2013 [14] 
None None Mean 
Median 
Tomotherapy 
(carotid-sparing) 
55 Gy/20 Daily MVCT - retrospective 
(planning study) 
Garcez et al 
2014 [15] 
 
Not reported None Maximum 
Mean 
Anterior wedged pair 50 Gy/16 No – planning study 
Janssen et al Not reported None Mean IMRT – 4 – 5 fields 66 – 70 Gy/33 - Yes – KV and CBCT 
2014 [16] V63, V50, V35 35 
Hong et al 2015 
[17] 
Max < 45 Gy None Maximum 
V63, V50, V35 
IMRT – 3 fields 
Tomotherapy 
67.5 Gy/30 Daily (retrospective planning 
study) 
Patient asked not to swallow  
Zumsteg et al 
2015 [18] 
Not reported Mean carotid 
< 52 Gy 
Median 
Mean 
V50, V40 
IMRT - 4 fields 63 Gy/28 No 
Matthiesen et al 
2015 [19] 
Not reported None Maximum 
Mean 
D20, D50, D90 
IMRT – 5 fields 
RapidArc – single arc 
Protons 
63 Gy/28 No – planning study 
Ward et al 
2015 [20] 
Not reported None Maximum 
Mean 
V50 
VMAT 63 Gy/28 Daily CBCT 
Patient asked not to swallow 
 
 
